301671-17-0

Basic information

• Product Name: methyl (R)-3-azido-2-[(tert-butyloxycarbonyl)amino]propionate
• Synonyms: methyl (R)-3-azido-2-[(tert-butyloxycarbonyl)amino]propionate
• CAS NO: 301671-17-0
• Molecular Weight: 244.25
• Mol File: 301671-17-0.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: methyl (R)-3-azido-2-[(tert-butyloxycarbonyl)amino]propionate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl (R)-3-azido-2-[(tert-butyloxycarbonyl)amino]propionate(301671-17-0)
• EPA Substance Registry System: methyl (R)-3-azido-2-[(tert-butyloxycarbonyl)amino]propionate(301671-17-0)

Safety Data

• Hazardous Substances Data: 301671-17-0(Hazardous Substances Data)

Upstream product

• 888331-01-9 (R)-methyl 2-((tert-butoxycarbonyl)amino)-3-((methylsulfonyl)oxy)propanoate 
• 126645-21-4 methyl N-(tert-butoxycarbonyl)-O-[(4-methylphenyl)sulfonyl]-D-serinate 
• 95715-85-8 2-(tert-butoxycarbonylamino)-3-hydroxypropionic acid methyl ester 

Downstream Products

• 225780-77-8 2-(R)-(tert-butoxycarbonyl)-amino-3-azidopropionic acid 
• 1389332-02-8 C₂₁H₂₉N₅O₇ 

Relevant articles and documents

Development of a solution-phase synthesis of minor groove binding bis-intercalators based on triostin A suitable for combinatorial synthesis

The development of a solution phase synthesis of azatriostin A (2) suitable for the preparation of combinatorial libraries enlisting only liquid-liquid acid/base extractions for the isolation and purification of all intermediates and the final product is disclosed.

Design, synthesis and antibacterial evaluation of novel 15-membered 11a-azahomoclarithromycin derivatives with the 1, 2, 3-triazole side chain

Macrolides are widely prescribed in clinic to treat various respiratory tract infections. However, due to their inappropriate use, the prevalence of macrolide-resistant strains among clinical isolates has become a concern for public health. Therefore, nov

Synthesis and biological evaluation (in Vitro and in Vivo) of cyclic arginine-glycine-aspartate (RGD) peptidomimetic-paclitaxel conjugates targeting integrin αvβ3

A small library of integrin ligand-paclitaxel conjugates 10-13 was synthesized with the aim of using the tumor-homing cyclo[DKP-RGD] peptidomimetics for site-directed delivery of the cytotoxic drug. All the paclitaxel-RGD constructs 10-13 inhibited biotinylated vitronectin binding to the purified αVβ3 integrin receptor at low nanomolar concentration and showed in vitro cytotoxic activity against a panel of human tumor cell lines similar to that of paclitaxel. Among the cell lines, the cisplatin-resistant IGROV-1/Pt1 cells expressed high levels of integrin αVβ3, making them attractive to be tested in in vivo models. cyclo[DKP-f3-RGD]-PTX 11 displayed sufficient stability in physiological solution and in both human and murine plasma to be a good candidate for in vivo testing. In tumor-targeting experiments against the IGROV-1/Pt1 human ovarian carcinoma xenotransplanted in nude mice, compound 11 exhibited a superior activity compared with paclitaxel, despite the lower (about half) molar dosage used.